Vir Biotechnology Inc (VIR)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -523,105 | -628,194 | 754,280 | 549,802 | -298,611 |
| Revenue | US$ in thousands | 74,205 | 86,180 | 1,580,470 | 1,087,070 | 76,368 |
| Pretax margin | -704.95% | -728.93% | 47.73% | 50.58% | -391.02% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-523,105K ÷ $74,205K
= -704.95%
The pretax margin of Vir Biotechnology Inc has exhibited significant fluctuations over the past five years. In December 2020, the company reported a negative pretax margin of -391.02%, indicating that its operating expenses and other charges exceeded its gross profit. However, by December 2021, the pretax margin improved substantially to 50.58%, signaling effective cost management and operational efficiency.
In the subsequent years, the company maintained relatively healthy pretax margins, with the figure standing at 47.73% in December 2022. This suggests that Vir Biotechnology Inc was able to sustain profitability and generate income before accounting for taxes and other expenses during this period.
However, in December 2023 and 2024, the company experienced significant downturns in its pretax margin, with figures of -728.93% and -704.95% respectively. These negative percentages indicate that the company incurred substantial losses and its expenses outweighed its revenues during these years.
Overall, the trend in Vir Biotechnology Inc's pretax margin reflects a mix of financial challenges and positive developments, highlighting the importance of closely monitoring and managing profitability to ensure long-term sustainability and growth.
Peer comparison
Dec 31, 2024